CN105130998A - 库潘尼西的制备方法 - Google Patents

库潘尼西的制备方法 Download PDF

Info

Publication number
CN105130998A
CN105130998A CN201510618067.6A CN201510618067A CN105130998A CN 105130998 A CN105130998 A CN 105130998A CN 201510618067 A CN201510618067 A CN 201510618067A CN 105130998 A CN105130998 A CN 105130998A
Authority
CN
China
Prior art keywords
preparation
pannixi
morpholine
base propoxy
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510618067.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105130998B (zh
Inventor
许学农
王喆
包志坚
张文件
苏健
顾新禹
薛佳
袁玉环
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd.
Original Assignee
SUZHOU LIXIN PHARMACY CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUZHOU LIXIN PHARMACY CO Ltd filed Critical SUZHOU LIXIN PHARMACY CO Ltd
Priority to CN201510618067.6A priority Critical patent/CN105130998B/zh
Publication of CN105130998A publication Critical patent/CN105130998A/zh
Application granted granted Critical
Publication of CN105130998B publication Critical patent/CN105130998B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
CN201510618067.6A 2015-09-25 2015-09-25 库潘尼西的制备方法 Active CN105130998B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510618067.6A CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510618067.6A CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法
KR1020187011225A KR102104957B1 (ko) 2015-09-25 2016-07-01 코판리십의 제조방법
PCT/CN2016/088091 WO2017049983A1 (zh) 2015-09-25 2016-07-01 库潘尼西的制备方法

Publications (2)

Publication Number Publication Date
CN105130998A true CN105130998A (zh) 2015-12-09
CN105130998B CN105130998B (zh) 2017-07-28

Family

ID=54716625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510618067.6A Active CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法

Country Status (3)

Country Link
KR (1) KR102104957B1 (und)
CN (1) CN105130998B (und)
WO (1) WO2017049983A1 (und)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法
CN108884496A (zh) * 2016-02-01 2018-11-23 拜耳制药股份公司 Copanlisib生物标志物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326307A2 (en) * 1988-01-23 1989-08-02 Kyowa Hakko Kogyo Co., Ltd. Novel pyridazinone derivatives and pharmaceutical preparations containing them
JP2003252875A (ja) * 2002-03-04 2003-09-10 Lotte Co Ltd 新規プリン誘導体
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯-嘧啶衍生物
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5210558B2 (ja) * 2007-07-12 2013-06-12 株式会社ブリヂストン 防振装置
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326307A2 (en) * 1988-01-23 1989-08-02 Kyowa Hakko Kogyo Co., Ltd. Novel pyridazinone derivatives and pharmaceutical preparations containing them
JP2003252875A (ja) * 2002-03-04 2003-09-10 Lotte Co Ltd 新規プリン誘導体
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯-嘧啶衍生物
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法
CN108884496A (zh) * 2016-02-01 2018-11-23 拜耳制药股份公司 Copanlisib生物标志物

Also Published As

Publication number Publication date
WO2017049983A1 (zh) 2017-03-30
CN105130998B (zh) 2017-07-28
KR102104957B1 (ko) 2020-04-28
KR20180096572A (ko) 2018-08-29

Similar Documents

Publication Publication Date Title
ES2794639T3 (es) Forma cristalina, método de preparación y compuesto intermedio de compuesto con anillo dihidropirido
AU2021261879A1 (en) Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
CN107573333B (zh) 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
CN105753944B (zh) 达卡他韦及其衍生物的制备中间体
CN106966947B (zh) 一种维格列汀的制备方法
CN105130998A (zh) 库潘尼西的制备方法
CN104910158A (zh) 具有生物活性的5,6,7,8-四氢吡啶并[3,4-d]嘧啶化合物及其制备方法和应用
CN110627801B (zh) 一类hdac抑制剂及其用途
CN106749259A (zh) 一种环戊基嘧啶并吡咯类化合物的合成方法
CN109608468B (zh) 一种枸橼酸托法替布杂质及其合成方法和用途
CN105985317B (zh) 一种色瑞替尼的制备方法及其中间体
CN105130997A (zh) 一种库潘尼西的制备方法
ES2837361T3 (es) Proceso para preparar compuestos de indol-carboxamida
CN104725292A (zh) 一种(s)(-)-氨磺必利的制备方法
EP3275882B1 (en) Process of synthesizing substituted pyridine and pyrimidine compound
CN105273023A (zh) 一种阿糖胞苷5’-o-l-缬氨酸酯盐酸盐的制备方法
CN105712919B (zh) 酰胺缩合剂在维格列汀合成方法中的应用
KR20210049130A (ko) 세고리식 화합물의 결정 형태 및 이의 용도
EP3257851B1 (en) Salt form and crystal form of 1,2,5 thiadiazolidin-1,1-dioxide, preparation method thereof and intermediate
CN104030958A (zh) 一种(s)-1-(2-氯乙酰基)吡咯烷-2-甲腈的合成方法
CN107814804A (zh) 依鲁替尼的制备方法
Zych et al. The effect of substitution patterns on the release rates of opioid peptides DADLE and [Leu5]-enkephalin from coumarin prodrug moieties
CN108003105B (zh) 一种合成小分子氨基酸衍生物依克多因的方法
CN112159462B (zh) 柯义巴肽a衍生物及其用途
CN104447952A (zh) 丙肝病毒蛋白酶抑制剂及其合成方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200714

Address after: Hu Suzhou high tech Zone of Jiangsu province 215151 City Road No. 21 Tang Guan District

Patentee after: SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd.

Address before: 215151 No. 21 West Tong Road, hi tech Development Zone, Jiangsu, Suzhou

Co-patentee before: Xu Xuenong

Patentee before: SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd.